Literature DB >> 28161038

Treatment of Infections Caused by Rhodococcus equi.

Steeve Giguère1.   

Abstract

Pneumonia caused by Rhodococcus equi remains an important cause of disease and death in foals. The combination of a macrolide (erythromycin, azithromycin, or clarithromycin) with rifampin remains the recommended therapy for foals with clinical signs of infection caused by R equi. Most foals with small, subclinical ultrasonographic pulmonary lesions associated with R equi recover without therapy, and administration of antimicrobial agents to these subclinically affected foals does not hasten lesion resolution relative to administration of a placebo. Resistance to macrolides and rifampin in isolates of R equi is increasing.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Macrolide; Pneumonia; Rhodococcus equi; Rifampin

Mesh:

Substances:

Year:  2017        PMID: 28161038     DOI: 10.1016/j.cveq.2016.11.002

Source DB:  PubMed          Journal:  Vet Clin North Am Equine Pract        ISSN: 0749-0739            Impact factor:   1.792


  9 in total

1.  VapA of Rhodococcus equi binds phosphatidic acid.

Authors:  Lindsay M Wright; Emily M Carpinone; Terry L Bennett; Mary K Hondalus; Vincent J Starai
Journal:  Mol Microbiol       Date:  2017-12-22       Impact factor: 3.501

2.  Novel Quantitative PCR for Rhodococcus equi and Macrolide Resistance Detection in Equine Respiratory Samples.

Authors:  Sonsiray Álvarez Narváez; Ingrid Fernández; Nikita V Patel; Susan Sánchez
Journal:  Animals (Basel)       Date:  2022-05-03       Impact factor: 3.231

Review 3.  Epidemiology and Molecular Basis of Multidrug Resistance in Rhodococcus equi.

Authors:  Sonsiray Álvarez-Narváez; Laura Huber; Steeve Giguère; Kelsey A Hart; Roy D Berghaus; Susan Sanchez; Noah D Cohen
Journal:  Microbiol Mol Biol Rev       Date:  2021-04-14       Impact factor: 11.056

4.  Clonal Confinement of a Highly Mobile Resistance Element Driven by Combination Therapy in Rhodococcus equi.

Authors:  Sonsiray Álvarez-Narváez; Steeve Giguère; Elisa Anastasi; Jack Hearn; Mariela Scortti; José A Vázquez-Boland
Journal:  mBio       Date:  2019-10-15       Impact factor: 7.867

5.  Spread of Multidrug-Resistant Rhodococcus equi, United States.

Authors:  Sonsiray Álvarez-Narváez; Steeve Giguère; Noah Cohen; Nathan Slovis; José A Vázquez-Boland
Journal:  Emerg Infect Dis       Date:  2021-02       Impact factor: 6.883

6.  International Spread of Multidrug-Resistant Rhodococcus equi.

Authors:  Jorge Val-Calvo; Jane Darcy; James Gibbons; Alan Creighton; Claire Egan; Thomas Buckley; Achim Schmalenberger; Ursula Fogarty; Mariela Scortti; José A Vázquez-Boland
Journal:  Emerg Infect Dis       Date:  2022-09       Impact factor: 16.126

7.  Antimicrobial Resistance Spectrum Conferred by pRErm46 of Emerging Macrolide (Multidrug)-Resistant Rhodococcus equi.

Authors:  Erdal Erol; Mariela Scortti; Jordan Fortner; Mukesh Patel; José A Vázquez-Boland
Journal:  J Clin Microbiol       Date:  2021-07-28       Impact factor: 5.948

8.  In vitro performances of novel co-spray-dried azithromycin/rifampicin microparticles for Rhodococcus equi disease treatment.

Authors:  Elisa Rampacci; Maria Luisa Marenzoni; Elisabetta Chiaradia; Fabrizio Passamonti; Maurizio Ricci; Marco Pepe; Mauro Coletti; Stefano Giovagnoli
Journal:  Sci Rep       Date:  2018-08-14       Impact factor: 4.379

9.  A Common Practice of Widespread Antimicrobial Use in Horse Production Promotes Multi-Drug Resistance.

Authors:  S Álvarez-Narváez; L J Berghaus; E R A Morris; J M Willingham-Lane; N M Slovis; S Giguere; N D Cohen
Journal:  Sci Rep       Date:  2020-01-22       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.